Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange 11:31:52 2024-12-05 am EST 5-day change 1st Jan Change
90.38 CHF +0.31% Intraday chart for Novartis AG -3.21% +6.49%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
NOVARTIS AG : Deutsche Bank remains Neutral Dec. 05 ZD
US Court Rejects Novartis' Appeal to Block Heart Failure Drug's Generic Version Dec. 04 MT
Novartis cannot block generic of best-selling heart drug, US appeals court says Dec. 04 RE
HSBC Downgrades Novartis to Reduce, Price Target is $95 Dec. 04 MT
NOVARTIS AG : JP Morgan reiterates its Neutral rating Dec. 03 ZD
Sector Update: Health Care Stocks Slipping Late Afternoon Dec. 02 MT
Sector Update: Health Care Stocks Softer Monday Afternoon Dec. 02 MT
Sector Update: Health Care Dec. 02 MT
PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate Dec. 02 MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday Dec. 02 MT
Sector Update: Health Care Dec. 02 MT
Novartis AG, PTC Therapeutics, Inc. - M&A Call Dec. 02
Olema Partners With Novartis for Clinical Trial of Potential Breast Cancer Drug, Launches $250 Million Stock, Warrant Placement Dec. 02 MT
PTC Therapeutics Shares Jump on Pact With Novartis Dec. 02 DJ
PTC Therapeutics Signs Exclusive Global License Deal With Novartis Unit for PTC518 Huntington's Disease Program; Shares Rise Premarket Dec. 02 MT
Swiss Market Index Recovers; Nestlé Shares Edge Up Nov. 27 MT
Global markets live: HP, Dell, Amazon, EasyJet, HSBC... Nov. 27Our Logo
Novartis Receives European Commission Approval for Adjuvant Early Breast Cancer Treatment Nov. 27 MT
Novartis Wins EU Approval for Expanded Use of Kisqali in Breast Cancer Treatment Nov. 27 MT
Novartis: has received authorization from the European Commission Nov. 27 CF
Novartis' Early Breast Cancer Drug Gets Approval from EU Commission Nov. 27 MT
EU Commission Approves Novartis' Kisqali in Broad Population of Breast Cancer Patients Nov. 27 MT
Novartis Kisqali(R) receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence Nov. 27 DJ
Novartis Kisqali Receives European Commission Approval in A Broad Population of Patients with HR+/HER2- Early Breast Cancer at High Risk of Recurrence Nov. 27 CI
Octavian AG Lifts Price Target on Novartis, Maintains Hold Recommendation Nov. 26 MT
Chart Novartis AG
NOVN: Dynamic Chart
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Employees
76,057
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
surperformance-ratings-light-chart NOVARTIS-AGMore Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
102.79USD
Average target price
115.73USD
Spread / Average Target
+12.59%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. NOVN Stock
  4. News Novartis AG
  5. Schrodinger Signs Research Partnership With Novartis for New Drug Discovery, Development